Surveillance Study of NovoRapid® for New Drug Re-examination

Regulatory Post Marketing Surveillance Study of NovoRapid for New Drug Re-examination

This study is conducted in Asia. The aim of this study is to observe the safety and efficacy of insulin aspart (NovoRapid®) administered via vial and three different devices.

Inclusion Criteria:

• Subjects with diabetes mellitus (type 1, type 2, or gestational) prescribed with insulin aspart (NovoRapid®)